Bayer-CuraGen: Gambling They Can Improve the Odds
Rather than spending to build the requisite infrastructure for a small-molecule program, CuraGen decided to partner, with Bayer, in a deal targeting metabolic disorders. But merely licensing out its small-molecule targets for current cash sells the future short which is why CuraGen was willing to forego cash payments in its deal. Instead, CuraGen is providing a capped $590 million in unreimbursed value to the program in return for what could be up to 44% of the profits from any one product. The only Bayer cash going into CuraGen's pocket is $135 million (albeit mostly equity) from a separate pharmacogenomics/toxicogenomics deal, without which it's questionable whether CuraGen could have afforded the Bayer alliance or whether Bayer itself would have agreed to it. The key point: Bayer aims to use the CuraGen pharmacogenomics technology to increase the predictability of its entire R&D effort and was thus willing to forego a significant piece of the end proceeds from the metabolic disease program.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.
House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.
The Perfectio device marketer came away from the advertising industry’s self-regulatory process with a number of claims intact or mostly untouched, though it discontinued a couple going into the assessment and the National Advertising Division advised against a few others. The firm has pledged to comply “in the spirit of compromise.”